Pagina inicial
Continue Watching
Últimos vídeos
Últimos vídeos
Brightcove Home Latest Listing
Oncology
Oncology
Brightcove Cards Listing
Hematology
Hematology
Brightcove Cards Listing
Popular em MedEnrich
Popular em MedEnrich
Popular in Sem nome
Oncospecials15m 30s
A Relevância dos Agentes TKI na era das imunoterapias para o tratamento do carcinoma de células Renais
ONCOPLUS apresenta: vídeo-aula com Dr. Denis Jardim na patologia de carcinoma de células renais.
oncologia
ccr
câncer renal
tki
sunitinibe
1
A Relevância dos Agentes TKI na era das...
Câncer de próstata11m 38s
Treatment Intensification in Metastatic Castration Sensitive Prostate Cancer
PEACE-1 clinical trial demonstrated that combining ADT and docetaxel with abiraterone acetate plus prednisone (AAP) improves both overall survival (OS) and radiographic progression-free-survival (rPFS) in men with de novo mCSPC.
treatment intensification
mhspc
triplet therapy
peace-1 clinical trial
1
Treatment Intensification in Metastatic Castration...
Myelodysplastic Syndromes23m 43s
Desenvolvimento e Atualizações na Biologia das Mielodisplasias
Desenvolvimento e Atualizações na Biologia das Mielodisplasias (MDS)
síndromes mielodisplásicas
mds
avanços na biologia
terapias inovadoras
epidemiologia da mds
1
Desenvolvimento e Atualizações na Biologia das...
Transplant15m 53s
Profilaxia de CMV em receptores de transplantes
Conheça as estratégias de profilaxia de CMV no pós-transplante de órgãos sólidos, melhor forma de manejo e monitorização de viremia.
cmv
hospitalar
valganciclovir
antiviral
manejo de viremia
transplante
1
Profilaxia de CMV em receptores de transplantes
Mieloma múltiplo7m 42s
MRD Assesment in Multiple Myeloma -Ready for Prime Time
Multiple Myeloma is an incurable disease with patients relapsing even after achieving deep responses. Minimal Residual Disease (MRD) represents a relatively new way of evaluating response to treatment.
minimum residual disease (mrd)
mrd negativity
multiple myeloma
1
MRD Assesment in Multiple Myeloma -Ready for Prime...
Myelodysplastic Syndromes14m 13s
ASH 2022 Update on Myelodysplastic Syndromes
ASH 2022 - Update on Myelodysplastic Syndromes
low risk mds
venetoclax
viale -a
eln classification
low dose lenalidomide
tags: azacitidine
1
ASH 2022 Update on Myelodysplastic Syndromes
Mieloma múltiplo9m 20s
Integrating Pomalidomide Based Regimens in Multiple Myeloma
Integrating pomalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (RRMM) involves using them as a core regimen, often combined with other agents like bortezomib or monoclonal antibodies for enhanced efficacy.
pomalidomide-dexamethasone
rrmm management
progression-free survival
combination therapies
1
Integrating Pomalidomide Based Regimens in Multiple...
nasopharyngeal carcinoma44m 35s
Comprehensive Overview of Nasopharyngeal Carcinoma
Over the last few years treatment of Nasopharyngeal Carcinoma has evolved with minimally invasive surgery, advances in chemotherapy & immunotherapy.
nasopharyngeal carcinoma
immunotherapy
1
Comprehensive Overview of Nasopharyngeal Carcinoma
Myelodysplastic Syndromes17m 56s
Papel da Azacitidina pós Transplante Alogênico - Dicussão Prática Clínica
Vídeo aula com discussão clínica entre 2 especialistas do Ac Camargo Cancer Center sobre o papel da azacitidina no tratamento de manutenção pós transplante alogênico de medula óssea.
smd
lma
azacitidina
transplante alogênico de medula
1
Papel da Azacitidina pós Transplante Alogênico -...
11m 28s
ESR1 Mutation in Hormone Receptor Positive Advanced Breast Cancer
ESR1 mutation leads to ligand independent activation of estrogen receptor. ESR1 mutations were first described in 1997 & their role remain underestimated as initial research was focused on primary tumor wherein these mutations were absent.
aromatase inhibitor resistance
hr +ve mbc
esr1 mutation
fulvestrant
1